Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Mould

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsD R Mould, A-C Walz, T Lave, et al.
Journal of Immunological Methods|October 12, 1995
Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assayB E Fayer, P P Soni, M H Binger, et al.
Journal of Clinical Pharmacology|December 15, 2011
Romiplostim dose response in patients with immune thrombocytopeniaJ J Perez-Ruixo, B Green, S Doshi, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecanS Akhtar, R A Beckman, D R Mould, et al.
Clinical Pharmacology and Therapeutics|July 1, 1995
Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepamD R Mould, T M DeFeo, S Reele, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritisD R Mould, C B Davis, E A Minthorn, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphomaD R Mould, K Sweeney, S B Duffull, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunitiesK Venkatakrishnan, L E Friberg, D Ouellet, et al.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsD R Mould, A-C Walz, T Lave, et al.
Journal of Immunological Methods|October 12, 1995
Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assayB E Fayer, P P Soni, M H Binger, et al.
Journal of Clinical Pharmacology|December 15, 2011
Romiplostim dose response in patients with immune thrombocytopeniaJ J Perez-Ruixo, B Green, S Doshi, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecanS Akhtar, R A Beckman, D R Mould, et al.
Clinical Pharmacology and Therapeutics|July 1, 1995
Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepamD R Mould, T M DeFeo, S Reele, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritisD R Mould, C B Davis, E A Minthorn, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphomaD R Mould, K Sweeney, S B Duffull, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunitiesK Venkatakrishnan, L E Friberg, D Ouellet, et al.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
Pageof 3